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Persistent infections with viruses such as HIV, Epstein–Barr virus, cytomelagovirus, and hepatitis B and C viruses continue
to be major human health problems. Immunocytotherapy for persistent viral infections has proven successful in animal
models but less effective in humans. While the requirement of antigen-specific CD81 T cells is known, the precise role of
CD41 T cells as regards specific priming, numbers needed, and interaction with CD81 T cells is less clear. To address these
issues, we used a mouse model of persistent virus infection in which adoptive transfer of T cells effectively purges virus from
all tissues. We demonstrate that (1) inclusion of antigen-specific CD41 in addition to CD81 T cells is mandatory for efficient
and long-term virus control. Neither naive nor CD41 T cells with specificity for a different virus are sufficient. (2) The minimal
numbers of virus-specific T cells required for virus clearance from sera and tissues are 350,000 virus-specific CD81 and
7000 virus-specific CD41 T cells or approximately 5 3 107 CD81 and as few as 1 3 106 CD41 T cells per square meter of
body surface area, a CD8:CD4 ratio of 50:1. (3) Production of interferon-g, obligatory for resolution of persistent infection, is
dependent on the interaction of virus-specific CD41 and CD81 T cells. (4) Maintenance of CD81 T cell effector functions after
adoptive transfer is directly proportional to the amount of cotransferred, virus-specific CD41 T cells. © 2000 Academic Press
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Similar to the control of most acute virus infections,
resolution of persistent virus infections is critically de-
pendent on MHC class I-restricted CD81 cytotoxic T
lymphocytes (CTL) (Oldstone, 1987; Zinkernagel and
Doherty, 1979). In addition, control of persistent infec-
tions requires the participation of CD41 T cells. Several
uman diseases illustrate the importance of CD41 help.
In HIV-infected individuals, diminished CD81 T cell ac-
ivity and high virus load are associated with loss of
D41 T cells (Borrow et al., 1997; Klein et al., 1995;
Rosenberg et al., 1997). Similarly, cytomegalovirus
CMV)-associated complications correlate closely with
he absence of CD81 and CD41 CMV-specific T cell
responses (Li et al., 1994), and Epstein–Barr virus (EBV)
reactivation occurs in the absence of EBV-specific T cell
immunity (Lucas et al., 1996). Murine studies have dem-
onstrated that CD41 T cells, although not required for
primary CTL responses (Tishon et al., 1995), are critical
for maintenance of virus-specific CD81 T cell function,
and absence of CD41 T cells leads to establishment of
irus persistence after infections with certain strains of
ymphocytic choriomeningitis virus (LCMV) (Matloubian
t al., 1994; Zajac et al., 1998), gammaherpes virus (Car-
1 These authors contributed equally to this work.
2 Current address: Department of Internal Medicine, Hematology/
Oncology, University of Freiburg, Hugstetter Strasse 55, D-79106
Freiburg, Germany.3 To whom correspondence and reprint requests should be ad-
dressed. Fax: (858) 784-9981.
25in et al., 1996), or Friend virus (Hasenkrug et al., 1998;
eviewed Kalams and Walker, 1998).
Conceptually, adoptive transfer of virus-specific, MHC-
atched immunocompetent cells constitutes a promis-
ng approach for prevention and/or treatment of persis-
ent viral infections in humans (Yee et al., 1997). However,
uman trials have not been uniformly successful. When
IV patients received virus-specific CD81 CTL clones,
irus clearance was not achieved and transferred clones
ere deleted (Riddell et al., 1996). A similar scenario was
bserved after prophylactic transfer of CMV-specific
D81 T cells that were deleted in the absence of endog-
enous CD4 help (Walter et al., 1995). A critical role for
CD41 T cells in immunocytotherapy was first observed in
he LCMV model of persistent infection. Transfer of
CMV-specific CD81 CTL alone failed to clear virus
(Byrne and Oldstone, 1986; Moskophidis et al., 1993)
unless CD41 T cells were also transferred (Planz et al.,
1997; Tishon et al., 1995). However, CD41 T cell numbers,
specificities, and their interaction with CD81 T cells in
ontrol of persistent virus infection remain unclear. The
esults presented here demonstrate that immunocyto-
herapy with virus-specific CD81 and CD41 T cells at a
50:1 ratio (minimal effective numbers: 350,000 CD81 and
7000 CD41 T cells) is effective and efficient for long-term
irus control. Cotransfer of naive or differentially primed
D41 T cells does not support virus clearance. Further-
ore, virus-specific CD41 T cells are essential for po-
entiation of cytokine production (IL-2 and interferon-g
1(IFN-g)), in vivo maintenance of virus-specific CD8 T
cells, and thus continued virus control.
0042-6822/00 $35.00
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258 BERGER, HOMANN, AND OLDSTONERESULTS AND DISCUSSION
To define parameters for CD41 T cell participation in
immunocytotherapy, we asked four questions: First,
must CD41 T cells be specifically primed by viral
antigen to sustain an effective antiviral CD81 CTL
esponse? Second, how many memory CD81 and
CD41 T cells are required for virus clearance? Third,
1
FIG. 1. (A) Specifically LCMV-primed but not Pichinde-primed or naive
Persistently LCMV-infected mice were infused with CD4-depleted sp
CMV-primed CD41 T cells (CD41LCMV), Pichinde-primed CD4
1 T cells
ice. (B–E) Cotransfer of 3.5 3 106 LCMV-primed CD81 (within a C
minimum of 4 to 7 3 105 CD41 T cells are required to clear virus. T
ndependent experiments.what are the minimal numbers of virus-specific CD8
and CD41 T cells needed to maintain long-term virusclearance? Fourth, how is maintenance of CD81 T cell
effector function altered in the presence and/or ab-
sence of CD41 T cells?
Virus-specific CD81 and CD41 T cells are required for
control of persistent virus infection. Figure 1A documents
the finding that LCMV-specific CD41 T cells were man-
datory for virus clearance when cotransferred with anti-
1
T cells are essential for purging virus from persistently infected hosts.
e populations containing 3.5 3 106 LCMV-primed CD81 T cells and
Pichinde), or naive CD4
1 T cells (CD41naive). Each group contained four
pleted population) and graded numbers of CD4LCMV
1 indicated that a
ere four mice per group. Results are representative for two or threeCD41
lenocyt
(CD41
D41-degen-primed LCMV-specific CD8 T cells. These obser-
vations are reminiscent of a recent investigation in which
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259IMMUNOCYTOTHERAPY OF PERSISTENT VIRAL INFECTIONsuccessful immunocytotherapy of EBV-related complica-
tions required transfer of polyclonal EBV-specific T cell
lines containing both CD81 and CD41 T lymphocytes
(Rooney et al., 1998), although the possible requirement
f non-EBV-activated or naive CD41 T cells was not
valuated. In our study, cotransfer of either naive or
ichinde-primed CD41 T cells with the same numbers of
CMV-specific CD81 T cells was not effective in virus
ontrol. Pichinde virus, like LCMV, is a member of the
renaviridae family but does not cross-react with LCMV
n the T cell level (Wright et al., 1995). The dose-depen-
ent, temporary virus titer reduction after cotransfer of
aive CD41 T cells may be due to limited expansion of in
vivo primed virus-specific precursors in the naive CD41 T
ell pool and is currently under investigation. Cotransfer
f Pichinde-primed CD41 T cells, even at high doses, did
ot affect virus titers.
LCMV-immune T cells control persistent infection
hen adoptively transferred at a CD8:CD4 ratio of 5:1. We
ext determined the number of primed CD81 and CD41
T cells required for successful immunocytotherapy. In
initial studies using bulk LCMV-memory splenocytes at
doses between 5 3 106 and 5 3 107, transfer populations
containing 3.5 3 106 CD81 T cells represented the lower
imit for reproducible and reliable virus clearance (data
ot shown). We then transferred 3.5 3 106 CD81 T cells
as part of a CD4-depleted LCMV-primed splenocyte pop-
ulation in combination with graded numbers of CD41 T
ells. Our results demonstrate that at least 7 3 105 CD41
T helper cells per mouse, i.e., at a CD8:CD4 ratio of 5:1,
were necessary for sustained viral clearance as deter-
mined by monitoring LCMV titers in sera (Figs. 1B–1E).
Analysis of tissues (PBMCs, spleen, liver, kidney, and
brain) harvested 100 days after adoptive transfers
showed that virus clearance was complete in all recipi-
ents having no detectable serum titers of infectious virus
(Fig. 2F; and data not shown).
Virus control is achieved with a minimum of 350,000
LCMV-specific CD81 and 7000 LCMV-specific CD41 T
cells. To assess the numbers of antigen-specific T cells
present in the transfer population, precursor frequencies
of LCMV-specific memory CD81 and CD41 T cells were
determined. As displayed in Table 1, CTL precursor fre-
quency analysis of whole splenocyte populations (1/45,
adjusted for CD81 T cells) and purified CD81 T cells
1/58) revealed similar numbers of CTL. However, about
ivefold more CD81 T cells (1/10) produced IFN-g and
tumor necrosis factor-a (TNF-a). While a discrepancy
etween CTL activity and cytokine production has been
oted previously (Oldstone et al., 1986; Guidotti et al.,
996), cytokine production correlates most closely with
ntigen specificity (Murali-Krishna et al., 1998). Of all
ytokine-producing CD81 T cells, around 90% coex-
pressed IFN-g and TNF-a. Interleukin 2 (IL-2)-producing
1 1D8 T cells (;1/50) were found only in this IFN-g /
TNF-a1 subset (Fig. 2A). Given the similar frequencies of
a
wCD81 CTL and CD81/IFN-g1/TNF-a1/IL-21 cells, we are
urrently investigating whether these cells belong to the
ame virus-specific CD81 T cell subset. Frequencies of
irus-specific CD41 T cells were generally lower: ;1/100
D41 T cells produced IFN-g after LCMV-specific stim-
lation and ;1/150–200 produced TNF-a and ;1/200
L-2 (Table 1). All TNF-a1 CD41 T cells also coexpressed
FN-g (Fig. 2B). All cytokine-producing CD81 and CD41 T
ells also expressed the activation/memory marker
D44high (data not shown). The virus-specific T cell fre-
quencies of ;1/10 CD81 and ;1/100 CD41 T cells and
he minimal numbers of CD81 and CD41 T cells required
for successful immunocytotherapy (Fig. 1C) allowed us to
calculate that a total of 350,000 LCMV-specific CD81 and
000 LCMV-specific CD41 T cells per mouse (CD8:CD4
atio of 50:1) are necessary for long-term virus control.
In vitro IFN-g and IL-2 production is potentiated in
ocultures containing virus-specific CD41 and CD81 T
cells. In contrast to the negligible role of cytokines such
as IL-2, IFN-g, and TNF-a in control of acute viral infec-
ion (Kundig et al., 1993; Tishon et al., 1995; Oldstone,
npublished data), both IFN-g and TNF-a are essential
or clearance of persistent infection (Guidotti et al., 1996;
Planz et al., 1997; Tishon et al., 1995; Oldstone, unpub-
lished data). CD41 T cells are major producers of IL-2
and have been proposed to promote continued cytokine
production, in particular of IFN-g, from activated CD81 T
cells (Kasaian et al., 1991; Su et al., 1998). To quantitate
cytokine production, defined numbers of virus-specific T
cells (Table 1) were cultured in the presence of LCMV-
infected antigen-presenting cells, and supernatants
were analyzed 48 h later for the presence of IL-2 and
IFN-g. In combination with the frequencies of cytokine-
roducing T cells, we were able to estimate the per cell
ecretion of IL-2 and IFN-g: on average, purified virus-
pecific CD41 T cells produced 23 fg/cell IL-2 and 200
g/cell IFN-g; comparatively, virus-specific CD81 T cells
ecreted 1.4 fg/cell IL-2 and 33 fg/cell IFN-g. An increase
in IL-2 (threefold) and IFN-g (fivefold) production was
observed in cocultures containing both LCMV-specific
CD41 and CD81 T cells (Figs. 2C and 2D). Such aug-
entation of cytokine production was absent in cocul-
ures containing naive or Pichinde-primed CD41 T cells,
indicating that the presence of both virus-specific CD41
and CD81 T cells is essential for potentiated cytokine
ecretion.
Maintenance of virus-specific CD81 T cell activity after
adoptive transfer is directly proportional to numbers of
cotransferred CD41 T cells. To further characterize the
ffect of CD41 on CD81 T cells in vivo, animals were
acrificed 60 days after cotransfer of a constant amount
f CD81 and graded numbers of CD41 T cells, and CD81
T cell activity was determined by virus-specific cytokine
production. As shown in Fig. 2E, the percentage of IFN-g-
1nd TNF-a-producing CD8 T cells correlated directly
ith the number of cotransferred LCMV-specific CD41 T
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260 BERGER, HOMANN, AND OLDSTONEFIG. 2. Analysis of virus-specific cytokine production by CD81 and CD41 T cells. (A and B) d60 LCMV-immune splenocytes were restimulated as
described under Materials and Methods and stained with a CyChrome conjugate for CD8 or CD4, followed by intracellular cytokine staining with
anti-TNFa-FITC, anti-IFNg-PE, and anti-IL-2-APC. Frequencies of virus-specific T cells were 1/10 CD81 and ;1/100 CD41 T cells. Numbers displayed
n quadrants indicate the percentage of all cytokine-producing T cells expressing IFN-g and/or TNF-a. IL-2-producing T cells (displayed in red) were
only found in the IFN-g1/TNF-a1 T cell subsets. Representative data for three independent experiments. (C and D) Secretion of IL-2 and IFN-g is
potentiated only in cocultures containing LCMV-specific CD81 and CD41 T cells. IL-2 and IFN-g levels were analyzed by ELISA in coculture
upernatants of LCMV-primed (L), Pichinde-primed (P), and naive (N) CD4-depleted and CD4-enriched splenocyte preparations. T cell-depleted
opulations did not produce either cytokine (data not shown). Cocultures of LCMV-primed CD4-depleted and CD4-enriched populations produced
ignificantly more IL-2 and IFN-g than any other combinations (P , 0.001). TNF-a was not detectable under these assay conditions, since it is largely
membrane bound. Results are representative for three independent experiments. (E) Maintenance of virus-specific CD81 T cell activity is dependent
n the number of cotransferred CD41 T cells. 60 days after cotransfer of 3.5 3 106 LCMV-primed CD81 and purified CD41 T cells containing the
indicated numbers of LCMV-specific CD41 T cells, virus-specific CD81 T activity in host spleens was assessed by intracellular staining for IFN-g and
TNF-a. In the critical range of 4–10 3 103 cotransferred virus-specific CD41 T cells, the percentage of virus-specific effector CD81 T cells was directly
roportional to the amount of transferred CD41 T cells (linear regression analysis). (F) Number of infected PBMCs correlates with cotransferred
irus-specific CD41 T cell input. 100 days after cotransfer of graded numbers of CD41 T cells as outlined above, PBMCs were harvested and analyzed
y infective center assay. Numbers of infected PBMCs are expressed as plaque-forming units (PFU) per 106 PBMCs. Infected PBMCs were detectedonly in mice that also exhibited detectable serum virus titers. Highest numbers were found in control animals infused with CD41 T cells only
right-hand column). Values in C, D, and F are expressed as means 6 SEM.
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261IMMUNOCYTOTHERAPY OF PERSISTENT VIRAL INFECTIONcells. While this correlation was observed in the range of
4–10 3 103 cotransferred virus-specific CD41 T cells,
cotransfers of 1 3 103 CD41 T cells, which did not result
n even temporary virus clearance from sera (Fig. 1D),
emonstrated ,0.7 and ,0.3% of CD81 T cells produc-
ng IFN-g and TNF-a, respectively. No IFN-g- or TNF-a-
1
TABLE 1
Frequencies of LCMV-Specific CD81 and CD41 T Cells 60 Days
after LCMV Infection Based on Different Effector Functions
Assay
Population
tested
Stimulation
witha
Parameter
testedb
Precursor
frequencyc
CD81 T cells
TL assay Whole spleen PECLCMV Killing 1/45
CD81 T cells PECLCMV Killing 1/58
ntracellular
cytokine
Whole spleen NP396/GP33/
GP276
IFN-g 1/9
stain Whole spleen NP396/GP33/
GP276
TNF-a 1/10
Whole spleen NP396/GP33/
GP276
IL-2 1/50
Whole spleen PECLCMV IFN-g 1/10
Whole spleen PECLCMV TNF-a 1/10
Whole spleen PECLCMV IL-2 1/53
CD41 T cells
ntracellular Whole spleen NP309/GP61 IFN-g 1/105
cytokine Whole spleen NP309/GP61 TNF-a 1/208
stain Whole spleen NP309/GP61 IL-2 1/200
Whole spleen PECLCMV IFN-g 1/127
Whole spleen PECLCMV TNF-a 1/154
Whole spleen PECLCMV IL-2 1/225
LISPOT Whole spleen NP309/GP61 IFN-g 1/212
Note. Virus-specific T cell frequencies were calculated based on
ifferent effector functions. 60 days after LCMV infection, splenic CD81
and CD41 T cells were restimulated and assayed for LCMV-specific
effector functions by CTL assay, intracellular cytokine staining, and
ELISPOT as described under Materials and Methods. Stimulation was
provided by LCMV-infected peritoneal exudate cells (PECLCMV) or the
indicated MHC class I- or class II-restricted LCMV peptides (Lewicki et
al., 1995; Whitmire et al., 1998). Precursor frequencies of CD81 CTL,
analyzed with whole spleen and purified CD81 T cell populations, and
f IL-21 CD81 T cells were ;1/50. IFN-g1 and TNF-a1 CD81 T cells
ere detected at frequencies of ;1/10. Cytokine1 CD41 T cells were
etected at frequencies of ;1/100–1/200. Results given are represen-
ative for pooled splenocyte populations or individual mice analyzed in
wo to five independent experiments.
a PECLCMV, LCMV-infected peritoneal exudate cells; NP396/GP33/GP276,
HC class I-restricted LCMV peptides NP396-404 (aa FQPQNGQFI),
P33-41 (KAVYNFATC), GP276-286 (SGVENPGGYCL); NP309/GP61, MHC
lass II-restricted peptides NP309-328 (SGEGWPYIACRTSVVGRAWE),
P61-80 (GLNGPDIYKGVYQFKSVEFD). Precursor frequencies of pep-
ide-specific T cells were determined separately and have been com-
ined in this table.
b IFN-g, interferon-g; IL-2, interleukin-2, TNF-a, tumor necrosis factor-
a.
c Precursor frequencies are expressed as virus-specific CD81 or
D41 T cell per total CD81 or CD41 T cells.roducing CD8 T cells were detected in recipients in-
used with 1 3 107 purified LCMV-immune CD41 T cells
a
sonly (data not shown). A similar relationship between
CD41 T cell input and CD81 T cell activity was observed
or in vitro target cell killing (data not shown). Thus, small
umerical variations in virus-specific CD41 T cells have
a profound effect on maintenance of CD81 T cell activity
n vivo and, hence, on effective virus control (Fig. 1F).
hese results may have implications for the observed
ailure of HIV-specific CTL to maintain control of HIV load
n the face of declining CD41 T cell counts.
In summary, our study delineates the minimal effective
numbers of T cells required for control of persistent
LCMV infection: 5 3 107/m2 virus-specific CD81 T cells
(calculated as cells/m2 body surface area (Dawson,
967)) in conjunction with 50-fold fewer CD41 T cells, i.e.,
1 3 106/m2, are sufficient for effective and efficient virus
learance from all organs tested. Furthermore, mainte-
ance of CD81 T cell effector function is directly propor-
ional to the number of transferred virus-specific CD41 T
ells that likely provide help via potentiation of cytokines
uch as IFN-g. Modest decreases in virus-specific CD41
T cells affect this balance and result in the inability of
antiviral CD81 T cells to control viral infection. While the
actual virus-specific T cell numbers and CD8:CD4 ratios
required for control of other persistent virus infections
may differ somewhat, the critical contribution by rela-
tively low numbers of virus-specific CD41 T cells is likely
to be a more general phenomenon and the T cell num-
bers reported here may serve as a guideline for future
studies in other persistent virus infections.
MATERIALS AND METHODS
Mice. Inbred C57BL/6J (H-2b) mice (B6) were obtained
from the rodent breeding colony at The Scripps Research
Institute (La Jolla, CA) and maintained under specific
pathogen-free conditions.
Virus, virus quantitation, and infection of mice. The
virus used was the Armstrong 53b strain (ARM) of LCMV.
In some experiments, Pichinde virus (kindly provided by
M. Buchmeier, The Scripps Research Institute) was used.
The origin of both viruses, their sequences, growth in
baby hamster kidney cells, and plaque assay on Vero
cells were previously described (Dutko and Oldstone,
1983). For acute virus infection, 6- to 10-week-old mice
were inoculated intraperitoneally (ip) with 1 3 105
plaque-forming units (PFU) of LCMV ARM. Control ani-
mals (naive mice) were mock infected in parallel with
vehicle. Persistently infected mice were generated by
intracranial inoculation of newborns with 5 3 103 PFU
CMV ARM or were obtained after in utero infection from
ersistently infected dams. Mice generated by either
ethod gave equivalent results.
Adoptive transfers. Erythrocyte-depleted splenocyte
uspensions were prepared from donor B6 mice 60 days
fter LCMV infection (day 60 splenocytes). Lymphocyte
ubsets were enriched or depleted using magnetic sep-
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262 BERGER, HOMANN, AND OLDSTONEaration techniques. Transfer populations were resus-
pended in 0.3 ml PBS and injected ip into persistently
infected adult recipients (mean body weight ;20 g) irra-
diated 24 h earlier (300 rad) (Homann et al., 1998).
Ex vivo depletion and enrichment. Transfer popula-
ions were depleted or enriched immediately before
doptive transfers by using antibody-coated magnetic
eads according to protocols provided by the manufac-
urers. Depletion of CD41 T and B cells was performed
using anti-CD4 and anti-B220 conjugated magnetic
beads (Dynal, Lake Success, NY). The purity of depleted
cells was .99.8% after one or two rounds of depletion.
Antibody cocktails for negative selection of CD41 T cells
(CD11b, B220, CD8, Ly-6G, and Ly-76) and CD81 T cells
CD11b, B220, CD4, Ly-6G, and Ly-76) (StemCell Tech-
ology, Vancouver, BC, Canada) were used to avoid co-
eceptor engagement. The purity of enriched cells was
95%.
Cytotoxic T lymphocyte precursors. For analysis of CTL
recursors, serial dilutions of day 60 spleen cells or
urified CD81 T cells were cultured for 8 days on MHC-
atched, irradiated (2000 rad), and LCMV-infected peri-
oneal exudate cells (PECLCMV) in the presence of T cell
growth factor and feeder cells. CTL activity was then
tested in a standard in vitro 51Cr release assay on LCMV-
infected and uninfected MC57 (H-2b) cells. Calculation of
TL precursors was as reported (Homann et al., 1998).
Flow cytometry. Staining for cell surface antigens, pre-
eded by Fc blocking (anti-CD16/CD32), was performed
sing anti-CD8-allophycocyanin (APC) or anti-CD8-Cy-
hrome, anti-CD4-CyChrome, anti-B220-phycoerythrin
PE), and anti-CD44-fluorescein (FITC) conjugates
PharMingen, La Jolla, CA). For intracellular cytokine
taining, spleen cells were stimulated for 5–10 h with
HC-matched, irradiated PECLCMV or PECnaive or for 5 h
with 50 U/ml recombinant human IL-2 (PharMingen) and
0.1 mg/ml MHC I-restricted (nucleoprotein (NP) amino
cids 396–404, glycoprotein (GP) 33-41, GP276-286
Lewicki et al., 1995); synthesized at TSRI Peptide Core
acility with purities as reported (Lewicki et al., 1995)) or
mg/ml MHC II-restricted (GP61-80, NP309-328 (Whit-
mire et al., 1998); made by Chiron Technologies, Clayton
Victoria, Australia; purity GP61-80 94%, NP309-328 86%)
LCMV peptides in the presence of 2 mg/ml brefeldin A.
Intracellular staining was performed as described (Ho-
mann et al., 1998) using anti-IFN-g PE, anti-TNF-a FITC,
and anti-IL-2 APC conjugates (PharMingen). Cells were
acquired on a FACScalibur flow cytometer (Becton Dick-
inson, San Jose, CA) and analyzed with Cell Quest (Bec-
ton Dickinson) or WinMDI (Joseph Trotter, La Jolla, CA)
software.
Cytokine ELISA. For quantitation of cytokine secretion,
spleens were harvested 60 days after LCMV, Pichinde, or
mock infection, and naive or memory CD41 T cell-de-
5 1pleted populations containing 1 3 10 CD8 T cells were
cocultured with 2 3 105 naive, LCMV, or Pichinde mem-ry CD41 T cells in the presence of irradiated PECLCMV or
ECnaive. Supernatant was collected 48 h later and stored
t 220°C for analysis of IFN-g and IL-2 in a sandwich
LISA (all antibodies and standards were from Phar-
ingen) as described (Homann et al., 1998). To enhance
sensitivity, an amplification step using 1 mg/ml ExtrAvidin
followed by 0.5 mg/ml anti-avidin–biotin (Sigma, St. Louis,
O) was introduced prior to incubation with strepta-
idin–HRP and color reaction. TNF-a was not detectable
under these assay conditions, since it is largely mem-
brane bound (data not shown).
Cytokine ELISPOT assay. For determination of IFN-g-
producing CD41 T cells, serial dilutions of day 60 spleen
cells were cultured for 36 h on anti-IFN-g (PharMingen)
coated MAHA plates (Millipore, Bedford, MA). Stimula-
tion for CD41 T cells was provided by 2 mg/ml GP61-80
and NP309-328 in the presence of 50 U/ml human IL-2
and syngeneic irradiated spleen feeder cells (5 3 106/
l). Use of anti-IFN-g detection antibody and color reac-
tion has been described (Whitmire et al., 1998).
Statistical analyses. Data handling and analysis (cal-
culation of precursor frequencies, standard error, signif-
icance) were performed using Prism 2.01 (GraphPad
Software, San Diego, CA).
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